Eupraxia Pharmaceuticals EPRX
NASDAQ EPRX
$8.24 -0.06 (-0.72%)
As of: Sep 30, 2026 · 10:18 AM EDT

Eupraxia Pharmaceuticals (EPRX) Short term Debt (2022)

Updated

Eupraxia Pharmaceuticals (EPRX) reported Short term Debt of $79,418 for the quarter ended Dec 31, 2022.

Analysis

Eupraxia Pharmaceuticals (EPRX) Short term Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Eupraxia Pharmaceuticals 328.04 Mn 326.44 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 79,418.00
API Access

Eupraxia Pharmaceuticals Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=EPRX&period=max&api_key=YOUR_API_KEY